MONTRONI, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 2.051
EU - Europa 1.268
AS - Asia 283
AF - Africa 5
OC - Oceania 5
SA - Sud America 1
Totale 3.613
Nazione #
US - Stati Uniti d'America 2.049
SE - Svezia 365
UA - Ucraina 284
DE - Germania 157
IE - Irlanda 145
SG - Singapore 103
DK - Danimarca 101
KR - Corea 66
GB - Regno Unito 65
FI - Finlandia 59
TR - Turchia 55
CN - Cina 54
FR - Francia 43
IT - Italia 31
BE - Belgio 15
CI - Costa d'Avorio 3
IN - India 3
NZ - Nuova Zelanda 3
AU - Australia 2
CA - Canada 2
MA - Marocco 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
CZ - Repubblica Ceca 1
NO - Norvegia 1
RU - Federazione Russa 1
TH - Thailandia 1
Totale 3.613
Città #
Chandler 347
Jacksonville 286
Boardman 158
Dublin 145
Wilmington 142
Fairfield 120
Ashburn 114
Ann Arbor 70
Seattle 69
San Mateo 66
Woodbridge 64
Houston 60
Lawrence 58
Princeton 58
Des Moines 52
New York 37
Singapore 34
San Diego 25
Cambridge 21
Brussels 15
Auburn Hills 9
Seoul 9
Beijing 8
Los Angeles 8
Norwalk 7
Washington 6
Shanghai 5
Hanover 4
Abidjan 3
Guangzhou 3
Marche 3
Pune 3
Quanzhou 3
Torre Annunziata 3
Wuhan 3
Frankfurt am Main 2
Helsinki 2
London 2
Auckland 1
Boston 1
Buffalo 1
Caraguatatuba 1
Cedar Rapids 1
Chicago 1
Chiswick 1
Christchurch 1
Civitanova Marche 1
Dalian 1
Dallas 1
Dubai 1
Hangzhou 1
Jesi 1
Jiaxing 1
Jining 1
Kilburn 1
Manchester 1
Modena 1
Oakville 1
Olomouc 1
Oslo 1
Perth 1
Phoenix 1
Redmond 1
Rome 1
San Tammaro 1
Shenzhen 1
Stockholm 1
Sydney 1
Taizhou 1
Toronto 1
Valle 1
Volga 1
Wellington 1
Wuxi 1
Totale 2.060
Nome #
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 97
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 95
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 86
Anticardiolipin antibodies expression in psoriasis 85
Effects of cryopreservation on lymphocyte immunophenotype and function 85
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults; results of a 48-week open-label, equivalence trial (CAN 3014) 82
Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. 82
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. 81
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. 80
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 80
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. 76
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 76
Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. 75
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 74
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 73
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. 72
Abnormal intracellular kinetics of cell –cycle-dependent proteins in lymphocytes from patients infected with human immunodeficiency virus: a novel biological link between immune activation, accelerated T- cell turnover and high levels of apoptosis 71
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. 70
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. 70
Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naïve for Antiretrovirals 69
Exogenous IL-2 administration corrects the cell cycle perturbation of lymphocytes from HIV-infected individuals 69
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? 68
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. 68
Sexual behaviour of heterosexual individuals with HIV infection naïve for antiretroviral therapy in Italy . 68
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 67
Unscheduled cyclin B expression and p34 cdc2 activation in T-lymphocytes from HIV patients 66
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. 65
Lo studio fenotipico delle cellule mononucleate, linee guida all'impiego clinico, alla lettura ed all'interpretazione nelle diverse condizioni morbose. 65
Cervical dysplasia in HIV-seropositive women: role of human papillomavirus infection and immune status 63
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis. 62
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. 62
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 62
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. 61
Lo studio fenotipico di linfociti e altre cellule mononucleate. 60
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. 60
Impact of Higly Active Antiretroviral Therapy on the Presenting Features and Outcome of Patients with Acquired Immunodeficiency Syndrome-Related Kaposi Sarcoma 58
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 58
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 58
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 58
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. 57
I vaccini, da Jenner ai vaccini a DNA 57
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 57
Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. 56
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. 54
Il paziente adulto con immunodeficienza. 53
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 52
Loss of CD127 (Interleukin-7 receptor) expression defines an expansion of “effector memory” CD8+Tcells in HIV-infected patients 50
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. 47
Infezione da HIV-1. 43
Low prevalence of primary mutations associated with drug resistance in antiviral-naïve patients at therapy initiation 43
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. 43
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 42
La diagnosi immunologica delle Malattie Autoimmuni non Organo Specifiche 41
Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the I.Co.N.A study 39
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 38
L’immunoricostituzione, un paesaggio dai mutevoli confini 37
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from tha italian cohort of antiretroviral-naïve patients study 36
Identikit della immunodeficienza da HIV. 30
Totale 3.652
Categoria #
all - tutte 15.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.969


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020256 0 0 0 0 57 1 60 0 58 5 2 73
2020/2021761 18 74 103 22 81 45 67 25 105 64 106 51
2021/2022441 13 96 2 61 8 21 8 43 26 56 23 84
2022/2023948 88 72 67 95 104 173 0 65 235 1 24 24
2023/2024404 85 11 17 73 70 62 8 8 0 4 12 54
2024/2025172 49 66 44 4 9 0 0 0 0 0 0 0
Totale 3.652